Seascape Capital Management Has $2.54 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Seascape Capital Management raised its position in Edwards Lifesciences Co. (NYSE:EW) by 3.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 34,262 shares of the medical research company’s stock after purchasing an additional 1,273 shares during the period. Seascape Capital Management’s holdings in Edwards Lifesciences were worth $2,536,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $30,000. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the period. Finally, Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EW. Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Canaccord Genuity Group upped their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 over the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $76.23 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market capitalization of $44.96 billion, a P/E ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. The company has a fifty day moving average price of $72.67 and a 200-day moving average price of $69.50.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.